checkAd

     130  0 Kommentare Admission to Trading on Euronext Brussels - Seite 2

    The Company has in total 2,437,960 outstanding options and 2,861,500 Restricted Stock Units, for the benefit of current and former staff and the managers of the group, conferring entitlement to subscribe for a maximum total of 5,299,460 new ordinary shares, each conferring one voting right.

    Contacts

    Acacia Pharma Group plc
    Mike Bolinder, CEO
    Gary Gemignani, CFO
    +44 1223 919760 / +1 317 505 1280
    IR@acaciapharma.com

     
    International Media
    Mark Swallow, Frazer Hall, David Dible
    Citigate Dewe Rogerson
    +44 20 7638 9571
    acaciapharma@citigatedewerogerson.com
     

    US Investors
    LifeSci Advisors
    Irina Koffler
    +1 917-734-7387
    ikoffler@lifesciadvisors.com
     

    Media in Belgium and the Netherlands
    Chris Van Raemdonck
    +32 499 58 55 31
    chrisvanraemdonck@telenet.be

    Acacia Pharma Group plc
    The Officers’ Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United Kingdom
    Company number 9759376

    About Acacia Pharma

    Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address.

    Acacia Pharma's first product, BARHEMSYS (amisulpride injection) is marketed in the US for the management of postoperative nausea & vomiting (PONV).

    BYFAVO (remimazolam) for injection, a very rapid onset/offset IV benzodiazepine sedative is approved and launched in the US for use during invasive medical procedures in adults lasting 30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion UK Limited for the US market.

    APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.

    Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D operations are centered in Cambridge, UK. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH.

    Seite 2 von 3


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Admission to Trading on Euronext Brussels - Seite 2 THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE …